76 related articles for article (PubMed ID: 28229376)
1. The Pharmacogenetics of Tacrolimus in Corticosteroid-Sparse Pediatric and Adult Kidney Transplant Recipients.
Madsen MJ; Bergmann TK; Brøsen K; Thiesson HC
Drugs R D; 2017 Jun; 17(2):279-286. PubMed ID: 28229376
[TBL] [Abstract][Full Text] [Related]
2. Composite CYP3A (CYP3A4 and CYP3A5) phenotypes and influence on tacrolimus dose adjusted concentrations in adult heart transplant recipients.
Liu M; Hernandez S; Aquilante CL; Deininger KM; Lindenfeld J; Schlendorf KH; Van Driest SL
Pharmacogenomics J; 2024 Feb; 24(2):4. PubMed ID: 38360955
[TBL] [Abstract][Full Text] [Related]
3. Implementation of Clinical Cytochrome P450 3A Genotyping for Tacrolimus Dosing in a Large Kidney Transplant Program.
Tillman E; Nikirk MG; Chen J; Skaar TC; Shugg T; Maddatu JP; Sharfuddin AA; Eadon MT
J Clin Pharmacol; 2023 Aug; 63(8):961-967. PubMed ID: 37042314
[TBL] [Abstract][Full Text] [Related]
4. A published pharmacogenetic algorithm was poorly predictive of tacrolimus clearance in an independent cohort of renal transplant recipients.
Boughton O; Borgulya G; Cecconi M; Fredericks S; Moreton-Clack M; MacPhee IA
Br J Clin Pharmacol; 2013 Sep; 76(3):425-31. PubMed ID: 23305195
[TBL] [Abstract][Full Text] [Related]
5. Attempted validation of 44 reported SNPs associated with tacrolimus troughs in a cohort of kidney allograft recipients.
Oetting WS; Wu B; Schladt DP; Guan W; Remmel RP; Dorr C; Mannon RB; Matas AJ; Israni AK; Jacobson PA
Pharmacogenomics; 2018 Feb; 19(3):175-184. PubMed ID: 29318894
[TBL] [Abstract][Full Text] [Related]
6. Cost-utility analysis of pharmacogenomics-guided tacrolimus treatment in Austrian kidney transplant recipients participating in the U-PGx PREPARE study.
Fragoulakis V; Koufaki MI; Joefield-Roka C; Sunder-Plassmann G; Mitropoulou C
Pharmacogenomics J; 2024 Mar; 24(2):10. PubMed ID: 38499549
[TBL] [Abstract][Full Text] [Related]
7. Immunosuppressant drug monitor: A non-invasive device to measure tacrolimus level in the saliva of transplanted patients.
Charlès L; Lupon E; Sheth T; Camuzard O; Lellouch AG; Shende C; Farquharson S; Safa K; Cetrulo CL
Int J Pharm; 2024 Mar; 653():123858. PubMed ID: 38286196
[TBL] [Abstract][Full Text] [Related]
8. The role of single nucleotide polymorphisms of CYP3A and ABCB1 on tacrolimus predose concentration in kidney transplant recipients.
Mlinšek G; Dolžan V; Goričar K; Buturović-Ponikvar J; Arnol M
Clin Nephrol; 2017 Supplement 1; 88(13):115-118. PubMed ID: 28655393
[TBL] [Abstract][Full Text] [Related]
9. Influence of CYP3A4 and CYP3A5 polymorphisms on tacrolimus and sirolimus exposure in stable kidney transplant recipients.
Tamashiro EY; Felipe CR; Genvigir FDV; Rodrigues AC; Campos AB; Hirata RDC; Tedesco-Silva H; Medina-Pestana JO
Drug Metab Pers Ther; 2017 May; 32(2):89-95. PubMed ID: 28593920
[TBL] [Abstract][Full Text] [Related]
10. The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation.
Lloberas N; Elens L; Llaudó I; Padullés A; van Gelder T; Hesselink DA; Colom H; Andreu F; Torras J; Bestard O; Cruzado JM; Gil-Vernet S; van Schaik R; Grinyó JM
Pharmacogenet Genomics; 2017 Sep; 27(9):313-322. PubMed ID: 28704257
[TBL] [Abstract][Full Text] [Related]
11. Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation.
Woillard JB; Mourad M; Neely M; Capron A; van Schaik RH; van Gelder T; Lloberas N; Hesselink DA; Marquet P; Haufroid V; Elens L
Front Pharmacol; 2017; 8():358. PubMed ID: 28642710
[TBL] [Abstract][Full Text] [Related]
12. Influence of tacrolimus metabolism rate on renal function after solid organ transplantation.
Thölking G; Gerth HU; Schuette-Nuetgen K; Reuter S
World J Transplant; 2017 Feb; 7(1):26-33. PubMed ID: 28280692
[TBL] [Abstract][Full Text] [Related]
13. Impact of the CYP3A5 genotype on the distributions of dose-adjusted trough concentrations and incidence of rejection in Japanese renal transplant recipients receiving different tacrolimus formulations.
Niioka T; Kagaya H; Saito M; Inoue T; Numakura K; Yamamoto R; Habuchi T; Satoh S; Miura M
Clin Exp Nephrol; 2017 Oct; 21(5):787-796. PubMed ID: 28271256
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of CYP3A5 Genomic Variances and Their Impact on Tacrolimus Dosing Requirements among Kidney Transplant Recipients in Eastern North Carolina.
Maldonado AQ; Asempa T; Hudson S; Rebellato LM
Pharmacotherapy; 2017 Sep; 37(9):1081-1088. PubMed ID: 28605053
[TBL] [Abstract][Full Text] [Related]
15. Effects of CYP3A4*22 and POR*28 variations on the pharmacokinetics of tacrolimus in renal transplant recipients: a meta-analysis of 18 observational studies.
Li Z; Wang X; Li D; Cheng S; Li Z; Guo H; Dong Y; Zheng Y; Li X
BMC Nephrol; 2024 Feb; 25(1):48. PubMed ID: 38321419
[TBL] [Abstract][Full Text] [Related]
16. Effects of
Kim JS; Shim S; Yee J; Choi KH; Gwak HS
Front Pharmacol; 2023; 14():1201083. PubMed ID: 37564175
[No Abstract] [Full Text] [Related]
17. Tacrolimus pharmacokinetics are influenced by CYP3A5, age, and concomitant fluconazole in pediatric kidney transplant patients.
Alghamdi A; Seay S; Hooper DK; Varnell CD; Darland L; Mizuno T; Lazear D; Ramsey LB
Clin Transl Sci; 2023 Oct; 16(10):1768-1778. PubMed ID: 37340713
[TBL] [Abstract][Full Text] [Related]
18. Association of P450 Oxidoreductase Gene Polymorphism with Tacrolimus Pharmacokinetics in Renal Transplant Recipients: A Systematic Review and Meta-Analysis.
Lee DH; Lee H; Yoon HY; Yee J; Gwak HS
Pharmaceutics; 2022 Jan; 14(2):. PubMed ID: 35213993
[TBL] [Abstract][Full Text] [Related]
19.
Mulder TAM; van Eerden RAG; de With M; Elens L; Hesselink DA; Matic M; Bins S; Mathijssen RHJ; van Schaik RHN
Front Genet; 2021; 12():711943. PubMed ID: 34306041
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
